- Home
- OAKU vs BEAT Comparison
OAKU vs BEAT Comparison
Compare OAKU & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OAKU
- BEAT
- Stock Information
- Founded
- OAKU 2022
- BEAT 2015
- Country
- OAKU Canada
- BEAT United States
- Employees
- OAKU N/A
- BEAT N/A
- Industry
- OAKU Blank Checks
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- OAKU Finance
- BEAT Technology
- Exchange
- OAKU Nasdaq
- BEAT Nasdaq
- Market Cap
- OAKU N/A
- BEAT 65.4M
- IPO Year
- OAKU 2023
- BEAT 2021
- Fundamental
- Price
- OAKU $11.56
- BEAT $1.95
- Analyst Decision
- OAKU
- BEAT Buy
- Analyst Count
- OAKU 0
- BEAT 1
- Target Price
- OAKU N/A
- BEAT $8.00
- AVG Volume (30 Days)
- OAKU 657.0
- BEAT 59.7K
- Earning Date
- OAKU 01-01-0001
- BEAT 03-13-2025
- Dividend Yield
- OAKU N/A
- BEAT N/A
- EPS Growth
- OAKU N/A
- BEAT N/A
- EPS
- OAKU 0.07
- BEAT N/A
- Revenue
- OAKU N/A
- BEAT N/A
- Revenue This Year
- OAKU N/A
- BEAT N/A
- Revenue Next Year
- OAKU N/A
- BEAT N/A
- P/E Ratio
- OAKU $160.63
- BEAT N/A
- Revenue Growth
- OAKU N/A
- BEAT N/A
- 52 Week Low
- OAKU $10.73
- BEAT $1.70
- 52 Week High
- OAKU $11.70
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- OAKU 67.40
- BEAT 37.85
- Support Level
- OAKU $11.28
- BEAT $1.81
- Resistance Level
- OAKU $11.70
- BEAT $2.03
- Average True Range (ATR)
- OAKU 0.01
- BEAT 0.10
- MACD
- OAKU -0.00
- BEAT -0.01
- Stochastic Oscillator
- OAKU 30.00
- BEAT 16.22
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.